Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors

AstraZeneca (AZN) shares underperformed the S&P 500 in the latest trading session, closing down 1.24%, though they outperformed the Medical sector over the past month. Investors anticipate upcoming earnings with projections of $1.11 EPS (12.12% YoY growth) and $14.03B in revenue (8.42% YoY growth); full-year estimates are $4.49 EPS and $57.68B revenue. AZN currently holds a Zacks Rank #3 (Hold), with its Forward P/E ratio at 16.2, a discount compared to the industry average of 20.51.

Analysis

AstraZeneca (AZN) concluded the latest trading session at $71.93, reflecting a 1.24% decline and underperforming the S&P 500, which gained 0.41%. Over the past month, AZN shares rose 0.54%, surpassing the Medical sector's 3.74% loss but lagging the S&P 500's 6.13% increase. Significant attention is on AstraZeneca's forthcoming earnings disclosure, with projections for earnings per share (EPS) of $1.11, a 12.12% year-over-year growth, and quarterly revenue of $14.03 billion, an 8.42% increase from the year-ago period. For the full year, consensus estimates anticipate an EPS of $4.49 (+9.25% YoY) and revenue of $57.68 billion (+6.67% YoY). Despite these positive growth forecasts, the Zacks Consensus EPS estimate has experienced a minor downward revision of 0.35% in the last month, and AstraZeneca currently holds a Zacks Rank of #3 (Hold). Valuation analysis indicates AZN is trading at a Forward P/E ratio of 16.2, which is a discount compared to its industry's average of 20.51. Furthermore, its PEG ratio stands at 1.34, below the industry average of 1.47. The company operates within the Medical - Biomedical and Genetics industry, which currently has a Zacks Industry Rank of 74, positioning it in the top 30% of over 250 industries, suggesting a relatively strong industry backdrop.

Key Decisions for Investors

• Investors should closely monitor AstraZeneca's upcoming earnings release, as the projected year-over-year growth of 12.12% in EPS and 8.42% in revenue will be critical in validating the current outlook, especially given the recent slight downward revision in consensus EPS estimates.
• The current valuation, with a Forward P/E of 16.2 and a PEG ratio of 1.34, both below industry averages, may present a relative value opportunity if growth targets are met or exceeded, warranting careful consideration alongside the 'Hold' rating.
• Given the direct correlation between analyst estimate revisions and near-term share price momentum, continued attention to any further changes in the Zacks Consensus EPS and the overall Zacks Rank #3 (Hold) status is prudent for assessing the stock's near-term trajectory.